Compare SYSCO Corporation (SYY) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SYSCO Corporation vs Zimmer Biomet Holdings Inc — how do they compare? SYSCO Corporation trades at $78.46 (market cap $38.47B), while Zimmer Biomet Holdings Inc trades at $88.84 (market cap $16.95B). The key difference: SYSCO Corporation is far larger — about 2.3× Zimmer Biomet Holdings Inc's market cap, and SYSCO Corporation pays the higher dividend (2.81%). Which is the better fit depends on your goals — on Pluang, investors hold SYSCO Corporation for 77 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| SYY | ZBH | |
|---|---|---|
Market Cap | $38.47B | $16.95B |
Volume | 4,808,465 | 2,505,240 |
Sector | Consumer Staples | Health |
52-Week High | $91.16 | $103.98 |
52-Week Low | $69.30 | $79.58 |
Typical Hold Time | 77 Days | 89 Days |
Enterprise Value | $51.65B | $24.02B |
Dividend Yield | 2.81% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYY trades at $78.31, up 1.98% today, with a neutral technical signal and mixed earnings history. The company reported revenue growth to $81.37B in 2025, though net income margin dipped to 2.08%. Recent news highlights a $500M AI efficiency program and a $1.5B senior notes offering, signaling strategic investments. Analyst consensus is bullish with a $85.75 price target, but the stock faces headwinds from high debt levels and competitive pressures.
The outlook for SYY is cautiously optimistic, supported by steady revenue growth and a strong analyst buy rating. Key opportunities include AI-driven cost savings and market expansion, while risks involve elevated leverage and margin compression. Investors should weigh the potential for earnings acceleration against macroeconomic sensitivity in the consumer staples sector.
Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
